Learning Optimal Dynamic Treatment Regimens Subject to Stagewise Risk Controls
Mochuan Liu, Yuanjia Wang, Haoda Fu, Donglin Zeng

TL;DR
This paper introduces a benefit-risk dynamic treatment regimen framework that optimizes personalized treatment strategies by balancing benefits and risks in sequential decision-making, with theoretical guarantees and real-world application.
Contribution
It proposes a novel weighted learning approach for DTRs that incorporates risk constraints, providing theoretical consistency and convergence analysis.
Findings
The method effectively balances benefit and risk in treatment decisions.
The approach is Fisher consistent and converges at a quantifiable rate.
Demonstrated success in simulations and T2D patient data.
Abstract
Dynamic treatment regimens (DTRs) aim at tailoring individualized sequential treatment rules that maximize cumulative beneficial outcomes by accommodating patients' heterogeneity in decision-making. For many chronic diseases including type 2 diabetes mellitus (T2D), treatments are usually multifaceted in the sense that aggressive treatments with a higher expected reward are also likely to elevate the risk of acute adverse events. In this paper, we propose a new weighted learning framework, namely benefit-risk dynamic treatment regimens (BR-DTRs), to address the benefit-risk trade-off. The new framework relies on a backward learning procedure by restricting the induced risk of the treatment rule to be no larger than a pre-specified risk constraint at each treatment stage. Computationally, the estimated treatment rule solves a weighted support vector machine problem with a modified smooth…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAdvanced Causal Inference Techniques · Statistical Methods in Clinical Trials · Health Systems, Economic Evaluations, Quality of Life
